Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0600097 (Sedation)
 1,337 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Status asthmaticus is a life-threatening episode of asthma that is refractory to usual therapy. Recent studies report an increase in the severity and mortality associated with asthma. In the airways, inflammatory cell infiltration and activation and cytokine generation produce airway injury and edema, bronchoconstriction and mucus plugging. The key pathophysiological consequence of severe airflow obstruction is dynamic hyperinflation. The resulting hypoxemia, tachypnea together with increased metabolic demands on the muscles of respiration may lead to respiratory muscle failure. The management of status asthmaticus involves intensive pharmacological therapy particularly with beta-adrenoceptor agonists (beta-agonists) and corticosteroids. Albuterol (salbutamol) is the most commonly used beta2-selective inhaled bronchodilator in the US. Epinephrine (adrenaline) or terbutaline, administered subcutaneously, have not been shown to provide greater bronchodilatation compared with inhaled beta-agonists. Corticosteroids such as methylprednisolone should be administered early. Aerosolized corticosteroids are not recommended for patients with status asthmaticus. Inhaled anticholinergic agents may be useful in patients refractory to inhaled beta-agonists and corticosteroids. In patients requiring mechanical ventilation, the strategy aims to avoid dynamic hyperinflation by enhancing expiratory time to allow complete exhalation. Complications of dynamic inflation are hypotension and barotrauma. Sedation with opioids, benzodiazepines or propofol is required to facilitate ventilator synchrony but neuromuscular blockade should be avoided as myopathy has been a reported complication. Overall, in the management of patients with status asthmaticus, the challenge to the pulmonary/critical care clinician is to provide optimal pharmacological and ventilatory support and avoid the adverse consequences of dynamic hyperinflation.
 ...
PMID:Management of respiratory failure in status asthmaticus. 1472 28

Sedation is often required to perform pulmonary function testing (PFT) in horses, but drug effects may influence respiratory function. The current study was designed to characterise the effects of sedation and bronchodilator administration on absolute and relative indices of pulmonary function during eupnoeic respiration and carbon dioxide-induced hyperpnoea (rebreathing) in healthy horses using a pneumotachographic spirometry system. Sedation with acetylpromazine (ACP), xylazine, or both drugs in combination was associated with significant reductions in respiratory frequency, minute ventilation and peak airflows during eupnoeic respiration. Peak expiratory airflow occurred later in the respiratory cycle than was observed in untreated horses, and expiratory relative flow-time indices were also affected during eupnoeic respiration. Rebreathing attenuated the effects of sedation on indices of pulmonary function, suggesting that future studies should consider the use of induced hyperpnoea as part of the spirometry protocol. Based on the finding that all sedative agents had some effect on eupnoeic respiration, albeit least pronounced with ACP, the latter drug should be considered for sedation of horses undergoing PFT. Salbutamol increased peak inspiratory flow during eupnoeic respiration in healthy horses.
 ...
PMID:Effects of sedation and salbutamol administration on hyperpnoea and tidal breathing spirometry in healthy horses. 2841 Jun 72